glp-1 kidney disease receptor agonists effects on established and presumed drivers of Kidney Outcomes With Glucagon-Like Peptide-1
Description
Research on GLP-1 for metabolic syndrome and early intervention Chicago
Manufacturers are investing heavily in expanding indications, developing higher-dose formulations, and advancing next-generation compounds
2 Lincoff AMBrown-Frandsen KColhoun HM Semaglutide 2023;389:2221-32
Larsen et al., 1997a
The review further distinguishes between established outcome benefits (CVD, CKD, and OSA) and conditions still under investigation (neurodegeneration, arthritis, and some liver endpoints)
Another limitation was incomplete or missing data, such as the maximum dose of administered GLP-1RAs
